37808130|t|The Effects of Ninjinyoeito on Impaired Spatial Memory and Prefrontal Cortical Synaptic Plasticity through alpha-Amino-3-hydroxy-5-4-isoxazole Propionic Acid Receptor Subunit in a Rat Model with Cerebral Ischemia and beta-Amyloid Injection.
37808130|a|Ninjinyoeito (NYT), a traditional Japanese medicine, is effective for improving physical strength and treating fatigue and anorexia. Recently, a clinical report revealed that NYT ameliorates cognitive dysfunction in Alzheimer's disease (AD) patients, although the mechanisms remain unclear. AD is a neurodegenerative disorder accompanied by a progressive deficit in memory. Current therapeutic agents are largely ineffective in treating cognitive dysfunction in AD patients. In this study, we investigated the effects of NYT on spatial memory impairment in a rat model of dementia. Rats were prepared with transient cerebral ischemia and intraventricular injection of beta-amyloid1-42 for 7 days (CI + Abeta). NYT was orally administered for 7 days after cerebral ischemia. We evaluated spatial memory using the Morris water maze and investigated the expression of alpha-amino-3-hydroxy-5-4-isoxazole propionic acid receptor subunits, the phosphorylation level of glutamate receptor A (GluA)1 at serine sites S831 and S845, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) in the hippocampus and prefrontal cortex of CI + Abeta rats. In the CI + Abeta rats, NYT treatment shortened the extended time to reach the platform. However, NYT did not restore the decrease in the hippocampal GluA1, GluA2, or CaMKII expression but increased prefrontal cortical phosphorylation levels of S845-GluA1 and CaMKII. Therefore, NYT may alleviate spatial memory impairment by promoting glutamatergic transmission involved in the phosphorylation of S845-GluA1 and CaMKII in the prefrontal cortex of CI + Abeta rats. Our results suggest that NYT is a valuable treatment for AD patients.
37808130	31	54	Impaired Spatial Memory	Disease	MESH:D008569
37808130	195	212	Cerebral Ischemia	Disease	MESH:D002545
37808130	352	359	fatigue	Disease	MESH:D005221
37808130	364	372	anorexia	Disease	MESH:D000855
37808130	432	453	cognitive dysfunction	Disease	MESH:D003072
37808130	457	476	Alzheimer's disease	Disease	MESH:D000544
37808130	478	480	AD	Disease	MESH:D000544
37808130	532	534	AD	Disease	MESH:D000544
37808130	540	566	neurodegenerative disorder	Disease	MESH:D019636
37808130	596	613	deficit in memory	Disease	MESH:D008569
37808130	678	699	cognitive dysfunction	Disease	MESH:D003072
37808130	703	705	AD	Disease	MESH:D000544
37808130	777	794	memory impairment	Disease	MESH:D008569
37808130	813	821	dementia	Disease	MESH:D003704
37808130	857	874	cerebral ischemia	Disease	MESH:D002545
37808130	938	940	CI	Disease	
37808130	943	948	Abeta	Gene	54226
37808130	996	1013	cerebral ischemia	Disease	MESH:D002545
37808130	1205	1225	glutamate receptor A	Gene	50592
37808130	1227	1233	GluA)1	Gene	50592
37808130	1370	1372	CI	Disease	
37808130	1375	1380	Abeta	Gene	54226
37808130	1394	1396	CI	Disease	
37808130	1399	1404	Abeta	Gene	54226
37808130	1537	1542	GluA1	Gene	50592
37808130	1544	1549	GluA2	Gene	29627
37808130	1637	1642	GluA1	Gene	50592
37808130	1692	1709	memory impairment	Disease	MESH:D008569
37808130	1790	1795	GluA1	Gene	50592
37808130	1835	1837	CI	Disease	
37808130	1840	1845	Abeta	Gene	54226
37808130	1909	1911	AD	Disease	MESH:D000544

